Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy

• DOI: 10.1021/acs.molpharmaceut.6b00932
• Publication Date: 2016-11-28T20:37:50Z
• Authors: Caifeng Deng; Mengdi Jia; Guangfei Wei; Tiantian Tan; Yao Fu; Huile Gao; Xun Sun; Quan Zhang; Tao Gong; Zhirong Zhang
• Keywords: Pirarubicin; Immunogenic cell death

Chemotherapeutic agents trigger antitumor immune response through inducing immunogenic tumor cell death. However, severe toxicity to system and insufficient death hinder chemotherapy from arousing efficient immunity in vivo. In this study, the cytotoxic drug, pirarubicin (THP), was entrapped into nanostructured lipid carriers (NLC); THP-NLC significantly reduced of THP improved status breast cancer bearing mice. When coinjected with iRGD (a tumor-penetrating peptide), drug accumulation tumors greatly elevated, which led significant control growth increase Subsequently, T lymphocytes (CD3+ CD8+ cells) infiltration cytokine (IFN-γ INF-α) secretion were heavily increased. The T-cell dependent late stage lower side effects contributed longest whole survival + treated Therefore, coadministration resulted increased direct-killing enhanced response. Our results illustrated that could serve as an inducer proposed delivery strategy might impact immunotherapy by